RARA CRAFT DATABASE for FDA Medical Devices
510(k)K183149

FDA DEVICE FACTS

Blue Non-Sterile Powder Free Nitrile Examination Gloves, Tested for Use with Low Dermatitis and Fentanyl Permeation Resistance Claim

Central Medicare Sdn Bhd

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJuly 4, 2019PRODUCT CODELZC

Indications for use

Blue Non Sterile Powder Free Nitrile Examination Gloves, Tested for Use with Chemotherapy Drugs, with Low Dermatitis and Fentanyl Permeation Resistance Claim is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. Low Dermatitis Potential - this product demonstrated reduced potential for sensitizing users to chemical additives. Tested for Use with Chemotherapy Drugs - Gloves have been tested for use with chemotherapy drugs using ASTM D6978-05 and will be labeled with a statement of compliance and a summary of the testing results. Chemotherapy Drug Permeation The following chemicals have been tested with these gloves: Tested Chemotherapy Drug Concentrate(mg/ml) Minimum Breakthrough Detection Time (minutes) Bleomycin Sulfate 15 >240 Busulfan 6 >240 Carboplatin 10 >240 *Carmustine 3.3 12.4 Cisplatin 1 >240 Chloroquine 50 >240 Cyclophosphamide 20 >240 Cyclosporin 100 >240 Cytarabine HCI 100 >240 Dacarbazine 10 >240 Daunorubicin HCI 5 >240 Docetaxel 10 >240 Doxorubicin Hydrochloride 2 >240 Epirubicin (Ellence) 2 >240 20 >240 25 >240 50 >240 38 >240 1 >240 50 >240 20 >240 Etoposide Fludarabine Fluorouracil Gemcitabine Idarubicin Ifosfamide Irinotecan Mechlorethamine HCI Melphalan Methotrexate Mitomycin 1 >240 5 >240 25 >240 0.5 >240 Mitoxantrone Oxaliplatin Paclitaxel Paraplatin Retrovir 2 >240 5 >240 6 >240 10 >240 10 >240 1 >240 1 >240 Trisonex Velcade Vincristine Sulfate 1 >240 * Please note that the following drugs have extremely low permeation times: Carmustine: 12.4 minutes and Thiotepa: 24.4 minutes

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 25, 2026